MAP2K7 and colorectal carcinoma: It would nevertheless be very interesting to define those subtypes in future research on BRAF/MEK and EGFR inhibition to confirm if screening for BM1 or BM2 at baseline could be used as predictive biomarker for sensitivity to targeted treatments in BRAFV600E mutant CRC.